JP2023533679A - 治療剤を局所的に送達するための薬物送達システムおよびその使用 - Google Patents

治療剤を局所的に送達するための薬物送達システムおよびその使用 Download PDF

Info

Publication number
JP2023533679A
JP2023533679A JP2022579760A JP2022579760A JP2023533679A JP 2023533679 A JP2023533679 A JP 2023533679A JP 2022579760 A JP2022579760 A JP 2022579760A JP 2022579760 A JP2022579760 A JP 2022579760A JP 2023533679 A JP2023533679 A JP 2023533679A
Authority
JP
Japan
Prior art keywords
methyl
amino
drug delivery
delivery system
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533679A5 (https=
Inventor
ジャーン，ハオ
ジャーン，ウエイジアン
フエン，リチュン
ウー，グオローン
リー，ダフェン
Original Assignee
コヴァル バイオファーマ （シャンハイ） カンパニー，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コヴァル バイオファーマ （シャンハイ） カンパニー，リミテッド filed Critical コヴァル バイオファーマ （シャンハイ） カンパニー，リミテッド
Publication of JP2023533679A publication Critical patent/JP2023533679A/ja
Publication of JP2023533679A5 publication Critical patent/JP2023533679A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022579760A 2020-07-15 2021-07-13 治療剤を局所的に送達するための薬物送達システムおよびその使用 Pending JP2023533679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/102115 2020-07-15
CN2020102115 2020-07-15
PCT/CN2021/105899 WO2022012492A1 (en) 2020-07-15 2021-07-13 Drug delivery system for locally delivering therapeutic agents and uses thereof

Publications (2)

Publication Number Publication Date
JP2023533679A true JP2023533679A (ja) 2023-08-04
JP2023533679A5 JP2023533679A5 (https=) 2024-07-12

Family

ID=79555042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579760A Pending JP2023533679A (ja) 2020-07-15 2021-07-13 治療剤を局所的に送達するための薬物送達システムおよびその使用

Country Status (10)

Country Link
US (1) US20230256106A1 (https=)
EP (1) EP4181963A4 (https=)
JP (1) JP2023533679A (https=)
KR (1) KR20230040957A (https=)
CN (2) CN115867319B (https=)
AU (1) AU2021310171A1 (https=)
BR (1) BR112022021179A2 (https=)
CA (1) CA3179897A1 (https=)
IL (1) IL297377A (https=)
WO (1) WO2022012492A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024506090A (ja) * 2021-02-09 2024-02-08 ミンフイ ファーマシューティカル （ハンチョウ） リミテッド プロドラッグ化合物、その製造方法、及び用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117355527B (zh) * 2021-07-20 2024-06-07 上海椿安生物医药科技有限公司 一种消炎偶联化合物药物及其制法和应用
JP2025505812A (ja) * 2022-02-21 2025-02-28 オンクオリティ ファーマシューティカルズ チャイナ リミテッド 化合物及びその用途
KR20250012423A (ko) * 2023-07-17 2025-01-24 차의과학대학교 산학협력단 금 나노입자 및 상환변환 나노입자로부터 형성된 일시적 광천공을 위한 나노복합체
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066214A1 (ja) * 2004-01-07 2005-07-21 Seikagaku Corporation ヒアルロン酸誘導体及びそれを含む薬剤
CN103751795A (zh) * 2013-05-20 2014-04-30 中国药科大学 透明质酸-抗肿瘤药偶联物及复合纳米粒组合物的制备和应用
WO2015005458A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
CA2609069A1 (en) * 2005-05-18 2006-11-23 Eurand Pharmaceuticals Limited Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
BRPI0910570A2 (pt) * 2008-04-22 2015-09-22 Fidia Farmaceutici uso de bioconjugados, e, formulações farmacêuticas
CN101745119B (zh) * 2010-01-25 2012-07-25 中国药科大学 羧酸类药物-多糖偶联物及其制备方法与应用
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
WO2014038641A1 (ja) * 2012-09-05 2014-03-13 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
KR101467076B1 (ko) * 2013-02-20 2014-12-02 성균관대학교산학협력단 히알루론산-메토트렉세이트 접합체를 포함하는 관절염 예방 또는 치료용 약학적 조성물 및 이의 제조방법
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
CN107096036B (zh) * 2017-04-12 2020-01-14 武汉理工大学 一种pH敏感型透明质酸-多柔比星纳米前药的制备方法及其应用
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
SG11202105128RA (en) * 2018-12-12 2021-06-29 Agency Science Tech & Res Conjugates and nanoparticles of hyaluronic acid and epigallocatechin-3-o-gallate and uses thereof
CA3181304A1 (en) * 2020-06-05 2021-12-09 Abdel-Rahman Lawendy Cannabinoid-hyaluronic acid bioconjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066214A1 (ja) * 2004-01-07 2005-07-21 Seikagaku Corporation ヒアルロン酸誘導体及びそれを含む薬剤
CN103751795A (zh) * 2013-05-20 2014-04-30 中国药科大学 透明质酸-抗肿瘤药偶联物及复合纳米粒组合物的制备和应用
WO2015005458A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIN WEI ET AL.: ""Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis"", MOLECULAR PHARMACEUTICS, vol. 15, no. 8, JPN7025002239, 2018, pages 3456 - 3467, ISSN: 0005734693 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024506090A (ja) * 2021-02-09 2024-02-08 ミンフイ ファーマシューティカル （ハンチョウ） リミテッド プロドラッグ化合物、その製造方法、及び用途

Also Published As

Publication number Publication date
KR20230040957A (ko) 2023-03-23
BR112022021179A2 (pt) 2023-02-23
CN117838875A (zh) 2024-04-09
EP4181963A1 (en) 2023-05-24
WO2022012492A1 (en) 2022-01-20
IL297377A (en) 2022-12-01
CN115867319A (zh) 2023-03-28
CA3179897A1 (en) 2022-01-20
AU2021310171A1 (en) 2022-11-10
EP4181963A4 (en) 2025-06-25
US20230256106A1 (en) 2023-08-17
CN115867319B (zh) 2024-01-02
CN117838875B (zh) 2025-01-24

Similar Documents

Publication Publication Date Title
JP2023533679A (ja) 治療剤を局所的に送達するための薬物送達システムおよびその使用
JP2023021283A (ja) シリコン系複合体
ES2307916T3 (es) Nuevo derivado de alfa-amino-n-(diaminofosfinil)lactama.
TWI578997B (zh) 用於預防或治療菸鹼成癮之共軛體
JP2018509441A (ja) 水溶性プロドラッグ
CA3252219A1 (en) THIOStrepton-inspired compounds for cancer treatment and related preparations
KR20250150111A (ko) 캄프토테신 유도체 및 이의 접합체, 이의 제조 방법 및 의학적 용도
AU2023378494A1 (en) Sting agonists
US20240398963A1 (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
CN103626825A (zh) 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CA3187159A1 (en) Ligand compounds, conjugates, and applications thereof
RU2847196C9 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
RU2847196C1 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
EP4190361A1 (en) Polyethylene glycol conjugate drug, and preparation method therfor and use thereof
HK40107352A (zh) 用於局部递送治疗剂的药物递送系统以及其用途
RU2697551C2 (ru) Новые производные peg
HK40107352B (zh) 用於局部递送治疗剂的药物递送系统以及其用途
US20200190101A1 (en) Composition Containing Novel Glutamic Acid Derivative And Block Copolymer, And Use Thereof
RU2849554C2 (ru) Конъюгат производного ε-поли-l-лизина с лекарственным средством, промежуточные соединения и их применение
WO2026002095A1 (en) Drug delivery system for locally controlled release of therapeutic agents and uses thereof
EP2313390B1 (en) Process for the preparation of nicotine-based haptens
HK40110475A (zh) 用於局部递送治疗剂的药物递送系统以及其用途
HK40069355B (zh) 化合物、缀合物及其用途
CN118108786A (zh) 连接组织蛋白酶b裂解的10-氨基喜树碱类化合物及其合成方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240704

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319